Literature DB >> 15601438

Plasma terminal half-life.

P L Toutain1, A Bousquet-Mélou.   

Abstract

Terminal plasma half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. When the process of absorption is not a limiting factor, half-life is a hybrid parameter controlled by plasma clearance and extent of distribution. In contrast, when the process of absorption is a limiting factor, the terminal half-life reflects rate and extent of absorption and not the elimination process (flip-flop pharmacokinetics). The terminal half-life is especially relevant to multiple dosing regimens, because it controls the degree of drug accumulation, concentration fluctuations and the time taken to reach equilibrium.

Mesh:

Substances:

Year:  2004        PMID: 15601438     DOI: 10.1111/j.1365-2885.2004.00600.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  62 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

Review 2.  The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values.

Authors:  Lik Hang N Lee; Charles Choi; Abby C Collier; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

3.  A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.

Authors:  Laetitia Canini; Annabelle Lemenuel-Diot; Barbara J Brennan; Patrick F Smith; Alan S Perelson
Journal:  Antivir Ther       Date:  2018

4.  Analysis of pharmacokinetics of Gd-DTPA for dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Saeid Taheri; N Jon Shah; Gary A Rosenberg
Journal:  Magn Reson Imaging       Date:  2016-04-22       Impact factor: 2.546

Review 5.  A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.

Authors:  Friederike Traunmüller; Martin Popovic; Karl-Heinz Konz; Patrick Vavken; Andreas Leithner; Christian Joukhadar
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

6.  Toxicokinetic study of pyrrole adducts and its potential application for biological monitoring of 2,5-hexanedione subacute exposure.

Authors:  Hong-Yin Yin; Ying Guo; Fu-Yong Song; Tao Zeng; Ke-Qin Xie
Journal:  Int Arch Occup Environ Health       Date:  2014-08       Impact factor: 3.015

7.  Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.

Authors:  Jonathan P Mochel; Martin Fink; Mathieu Peyrou; Antoine Soubret; Jérôme M Giraudel; Meindert Danhof
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

8.  Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.

Authors:  Mengxin Geng; Akshaya Ravichandran; Jerome Escano; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

9.  Biomonitoring of chlorpyrifos exposure and health risk assessment among applicators on rice farms in Ghana.

Authors:  Albert Atabila; Ross Sadler; Dung Tri Phung; Jonathan N Hogarh; Stewart Carswell; Scott Turner; Renu Patel; Des Connell; Cordia Chu
Journal:  Environ Sci Pollut Res Int       Date:  2018-05-15       Impact factor: 4.223

10.  Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs.

Authors:  Brian J Smith; Stephen M Kirschner; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-09-02       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.